How Medicines Law & Policy
is Aiding the Covid-19 Response
SEE COVID RESOURCES
European Union Review of Pharmaceutical Incentives:
Suggestions for Change
A new briefing paper series from Medicines Law & Policy
READ MORE
EU Review of Pharmaceutical
Incentives: Suggestions for Change
Medicines Law & Policy creates tools countries and others looking to increase access to medicines can use to overcome patent barriers when needed.
OUR TOOLS
Medicines Law & Policy maintains a database
documenting use of TRIPS Flexibilities
to increase access to medicines worldwide.
ACCESS THE TRIPS FLEXIBILITIES DATABASE
Medicines Law & Policy releases analysis,
policy recommendations and tools to aid practitioners
working on universal access to medicines.
OUR RESOURCES

Latest Posts

The elephant in the room at the WHO Executive Board

The World Health Organization (WHO) Director-General, Dr Tedros Adhanom Ghebreyesus spoke harshly about the lack of Covid-19 vaccines in developing countries at the opening of...

Wrapping up 2020 with some noteworthy medicines, law and policy events

Wrapping up the year 2020 can’t happen soon enough. This year, one way or the other, most people on the planet have been affected...

Decision on intellectual property waiver over Covid technology on hold till 2021; what are...

Note: This article was edited on 19 December to include a statement from the EU supporting sharing of intellectual property, technology, and know-how transfer. The...

What is the ‘know-how gap’ problem and how might it impact scaling up production...

This entire article is also available as a PDF by clicking here. 1. Introduction. How relevant are concerns about intellectual property rights causing problems for...

Ellen ‘t Hoen named one of the “50 Most Influential People in IP”

For Ellen ‘t Hoen's "fierce" advocacy on access to medicine, and in particular for her efforts under the Covid-19 pandemic to ensure knowledge and...

Some Surprises in the European Commission’s New Intellectual Property Strategy

The European Commission's new intellectual property (IP) strategy is out and it holds a number of surprises for access to medicines. After restating the...

Never miss a post! Sign up for ML&P's mailing list by entering your information below. The list will only be used to inform you of new content (messages are sent approximately once a month).